AtaiBeckley Inc. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Eli Lilly and Company has agreed to acquire AtaiBeckley Inc. via merger with subsidiary Albali Acquisition Corporation. Merger consideration: $6.75 per share in cash at closing plus one contingent value right (CVR) per share representing potential milestone payments if achieved post-closing. AtaiBeckley shareholders will receive no guaranteed upside beyond $6.75; CVR payments are expressly not guaranteed and Parent makes no commitment to achieve milestones. Deal dated July 15, 2026; Company Board unanimously approved and supports the transaction.
Why this rating
At $361M market cap, $6.75/share all-cash exit with potential CVRs represents a transformational event—full company sale to major pharma. High significance due to company dissolution and certainty of $6.75 consideration.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.